SOPHiA GENETICS SA (SOPH) Stock Forecast: StockMap's 2-Week Call
SOPH stock forecast: StockMap's model makes no two-week call on SOPHiA GENETICS SA after the Nov 19 close: its evidence is split, 7 reasons for and 8 against. Too few two-week windows graded to judge yet.
SOPHiA GENETICS SA last closed at $6.68, -10.58% on the session.
Against the IVW growth benchmark the position is -8.25% over the forecast window.
SOPHiA GENETICS SA's market cap is $572.17M as of November 19, 2026.
No call today: the model sees no clear direction · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is 6 (too close to call).
Where SOPH sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 7 bullish and 8 bearish.
Agreement across those insights is 47%.
3 daily calls for SOPH so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks SOPHiA GENETICS SA in the 8th percentile on return on equity, where 100 is best.
SOPHiA GENETICS SA is classified under Health Care / Health Care Technology.
StockMap tracks SOPHiA GENETICS SA as the 11th largest of the 21 companies it covers in the Health Care Technology industry, part of the Health Care sector.
Across that group the current two-week reads are 15 Neutral, 3 Moderate Underperform and 3 Strong Underperform.
On that composite SOPHiA GENETICS SA ranks 6th of 21 in the group, against a group median of -0.01.